Evidence map›Paper›PMID 35055357›Full record

ArticleJournal of personalized medicine2022

COL-3-Induced Molecular and Ultrastructural Alterations in K562 Cells.

Mona Fares, Sandra Oerther, Kjell Hultenby, Danica Gubrianska, Ying Zhao, Manuchehr Abedi-Valugerdi, Moustapha Hassan

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  2. Review
  3. CuO-TiOBioinorganic chemistry and applications · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mona FaresExperimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Sandra OertherExperimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Kjell HultenbyDepartment of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, 141 57 Huddinge, Sweden.
Danica GubrianskaExperimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Ying ZhaoExperimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Manuchehr Abedi-ValugerdiExperimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.
Moustapha HassanExperimental Cancer Medicine, Division of Biomolecular and Cellular Medicine (BCM), Department of Laboratory Medicine, Novum, Karolinska Institutet, 141 57 Huddinge, Sweden.ORCID 0000-0003-1927-5859
Karolinska University Hospital · SE

Funding

Barncancerfonden PR2020-0151Karolinska Institute 2018-02377Karolinska Institute 20200788 (CiMED)Radium Hemmets Research Funds 161082Swedish Cancer Society CAN2011/595
6 · The paper itself

Abstract

Tetracycline-3 (4-dedimethylamino sancycline, COL-3) is a non-antibiotic tetracycline derivative. COL-3 exerts potent anti-metalloproteinase activity and its antitumor effects have been reported both in vitro and in vivo. In this study, we investigated the mechanisms of COL-3-induced cytotoxicity in a chronic myeloid leukemia cell line, K562, characterized by the BCR-ABL fusion protein. COL-3 induced K562 cell death in a concentration-dependent manner with an IC50 of 10.8 µg/mL and exhibited features of both apoptosis and necrosis. However, flow cytometry analysis revealed that necrotic cells dominated over the early and late apoptotic cells upon treatment with COL-3. Transmission electron microscopy analysis in combination with Western blotting (WB) analysis revealed early mitochondrial swelling accompanied by the early release of cytochrome c and truncated apoptosis inducing factor (tAIF). In addition, ultrastructural changes were detected in the endoplasmic reticulum (ER). COL-3 affected the levels of glucose-regulated protein-94 (GRP94) and resulted in m-calpain activation. DNA double strand breaks as a signature for DNA damage was also confirmed using an antibody against γH2AX. WB analyses did not demonstrate caspase activation, while Bcl-xL protein remained unaffected. In conclusion, COL-3-induced cell death involves DNA damage as well as mitochondrial and ER perturbation with features of paraptosis and programmed necrosis.

Indexed as

COL-3K562 cellsm-calpainparaptosisprogrammed necrosis

Identifiers

PMID35055357
PMCPMC8778770
OpenAlexW4206019160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.